Formats
  1. Journal Article (66746)
  2. Meeting Abstract (33620)
  3. Book Section (5027)
  4. Review (3744)
  5. Editorial (2162)
  6. Conference Paper (1525)
  7. Correspondence (661)
  8. Guidelines (660)
  9. Research Letter (548)
  10. Miscellaneous (339)
  11. Book Whole (338)
Groups
  1. Department of Medicine (39033)
  2. GSK Faculty (22468)
  3. Solid Tumor Oncology Division (22056)
  4. Surgery (21247)
  5. Sloan Kettering Institute Faculty (16086)
  6. Survivorship Research (15762)

More Groups

People
  1. Marc Ladanyi (1327)
  2. Robert Motzer (1243)
  3. Victor Reuter (1228)
  4. Howard Scher (1130)
  5. Murray Brennan (1059)
  6. Sergio Giralt (1050)

More People

Years
  1. 2025 (1982)
  2. 2024 (5377)
  3. 2023 (5804)
  4. 2022 (6168)
  5. 2021 (5712)
  6. 2020 (5598)

More Years

Publications
  1. Journal of Clinical Oncology (8590)
  2. Blood (4950)
  3. Cancer Research (2701)
  4. International Journal of Radiation Oncology, Biology, Physics (2610)
  5. Laboratory Investigation (1879)
  6. Modern Pathology (1812)

More Publications

Publishers
  1. Elsevier Inc. (13855)
  2. American Society of Clinical Oncology (9157)
  3. Springer (7152)
  4. Nature Publishing Group (6367)
  5. American Association for Cancer Research (6002)
  6. Elsevier Science, Inc. (5503)

More Publishers

Results (115370)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • POLO: Long-term safety and tolerability of olaparib for patients with a germline BRCA mutation and metastatic pancreatic cancer
    Meeting Abstract

    Kindler, H. L.; Golan, T.; Hammel, P.; Reni, M.; Van Cutsem, E.; Macarulla, T.; Hall, M. J.; Park, J.; Hochhauser, D.; Oh, D.; more...
    Pancreas (2021)

    Fulltext@MSK | Save
  • Patient Reported Outcomes and Financial Toxicity in Head and Neck Cancer (PaRTNer): Baseline financial toxicity and attitudes toward costs from a pilot study
    Meeting Abstract

    Chino, F.; Brizel, D. M.; Mowery, Y. M.
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • US health utility in advanced non-small cell lung cancer (NSCLC) patients harboring MET exon 14 (METex14) skipping mutations treated with tepotinib
    Meeting Abstract

    Paik, P. K.; Yang, M.; Knowles, E.; Hatswell, A.; Vioix, H.; Liu, F. X.
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Suboptimal clinician awareness of appropriate NTRK fusion testing and TRK inhibitor use in solid tumors
    Meeting Abstract

    Topping, R. P.; Marcello, K.; Fagan, T.; Quill, T. A.; Bauer, T. M.; Drilon, A. E.; Demetri, G. D.
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Radiotherapy contour quality improvement practices among United States radiation oncologists
    Meeting Abstract

    Zhang, H.; Cha, E.; Lynch, K.; Gennarelli, R. L.; Sherer, M. V.; Brower, J. W.; Golden, D. W.; Royce, T. J.; Chimonas, S.; Korenstein, D.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Trends in diagnosis and treatment of early breast cancer (eBC) in the United States (US) during the COVID-19 era
    Meeting Abstract

    Ackerman, B.; Keane, C.; Beaver, J. A.; Kluetz, P. G.; Rivera, D.; Paliwal, P.; Singh, H.; Mpofu, P.; Amiri-Kordestani, L.; Baxi, S. S.
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • The impact of race, education, and employment status on cost-coping strategies and patient reported benefit from interventions to mitigate financial toxicity
    Meeting Abstract

    Braxton, K.; Thom, B.; Brown, C. L.; Gany, F.; Chino, F.; Aviki, E. M.
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Disaggregating Pacific Islanders and major Asian subpopulations to reveal hidden breast cancer disparities
    Meeting Abstract

    Taparra, K.; Dee, E. C.; Dao, D.; Patel, R.; Santos, P. M. G.; Chino, F.
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Is the maximum tolerated dose (MDT) still the optimal goal for cancer drugs?
    Meeting Abstract

    Norton, L.
    Breast (2021)

    Fulltext@MSK | Save
  • The alpelisib (ALP) experience in the SOLAR-1 and BYLieve studies: Perspectives for practitioners caring for patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC)
    Meeting Abstract

    Rugo, H. S.; AndreĢ, F.; Park, Y. H.; Drullinsky, P.; Loibl, S.; Cardoso, F.; Mason, G.; Aubel, D.; Lorenzo, I.; Akdere, M.; more...
    Breast (2021)

    Fulltext@MSK | Save